pteridines has been researched along with Breast Cancer in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most common therapy for estrogen receptor-positive breast cancer is antihormone therapy, such as tamoxifen." | 7.88 | Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer. ( Bui, QT; Hong, J; Im, JH; Jeong, SB; Kang, KW; Lim, SC; Shim, Y; Song, JM; Yoon, JH; Yun, J, 2018) |
| " Effects of TG100-115 on breast cancer cell proliferation, migration, invasion, myosin IIA phosphorylation, and TRPM7 ion channel activity were assessed by using MTT, wound healing, transwell assay, Western blotting, and patch clamping, respectively." | 7.85 | Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion. ( Bae, Y; Hur, W; Jun, J; Kim, ND; Lee, H; Lee, KB; Park, JY; Sim, T; Song, C, 2017) |
| "Recent preliminary studies have implicated urinary pteridines as candidate biomarkers in a growing number of malignancies including breast cancer." | 7.79 | Simultaneous detection of six urinary pteridines and creatinine by high-performance liquid chromatography-tandem mass spectrometry for clinical breast cancer detection. ( Burton, C; Ma, Y; Shi, H, 2013) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 6.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Tamoxifen resistance is a multifaceted phenomenon, characterized by the constitutive activation of multiple signaling cascades that provide an additional survival advantage to cells." | 5.42 | BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells. ( Bharti, R; Mandal, M; Parida, S; Prashanth Kumar, BN; Rajput, S, 2015) |
| "First, MCF10AT breast cancer cells were dosed individually with 15 pteridines to determine which pteridines were being metabolized and what metabolic products were being produced." | 4.12 | Establishing pteridine metabolism in a progressive isogenic breast cancer cell model - part II. ( Burton, C; Foulks, Z; Rasmussen, L; Shi, H; Wu, J, 2022) |
| " In breast cancer, this metabolic pathway becomes dysregulated, resulting in the excretion of certain pteridine derivatives and providing in vitro evidence for the observation of elevated pteridines in the urine of breast cancer patients." | 4.02 | Establishing pteridine metabolism in a progressive isogenic breast cancer cell model. ( Burton, C; Foulks, Z; Rasmussen, L; Shi, H, 2021) |
| "The most common therapy for estrogen receptor-positive breast cancer is antihormone therapy, such as tamoxifen." | 3.88 | Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer. ( Bui, QT; Hong, J; Im, JH; Jeong, SB; Kang, KW; Lim, SC; Shim, Y; Song, JM; Yoon, JH; Yun, J, 2018) |
| " Effects of TG100-115 on breast cancer cell proliferation, migration, invasion, myosin IIA phosphorylation, and TRPM7 ion channel activity were assessed by using MTT, wound healing, transwell assay, Western blotting, and patch clamping, respectively." | 3.85 | Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion. ( Bae, Y; Hur, W; Jun, J; Kim, ND; Lee, H; Lee, KB; Park, JY; Sim, T; Song, C, 2017) |
| " In 48 aggressive and benign breast cancers, normalization by USG significantly outperformed creatinine adjustments which marginally outperformed uncorrected pteridines in predicting pathological status." | 3.80 | Normalization of urinary pteridines by urine specific gravity for early cancer detection. ( Burton, C; Ma, Y; Shi, H, 2014) |
| "Recent preliminary studies have implicated urinary pteridines as candidate biomarkers in a growing number of malignancies including breast cancer." | 3.79 | Simultaneous detection of six urinary pteridines and creatinine by high-performance liquid chromatography-tandem mass spectrometry for clinical breast cancer detection. ( Burton, C; Ma, Y; Shi, H, 2013) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 2.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Results indicated DHA inhibited breast cancer cell proliferation and migration, with more potent effects compared with that of artemisinin." | 1.56 | Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling. ( Gao, N; He, Q; Ji, J; Li, Y; Liu, J; Ma, L; Wang, Q; Yang, R; Zhou, X, 2020) |
| " Nonetheless, despite overexpressing PLK1, in our model, expressive results after its inhibition were only seen through clonogenic assays or when BI 6727 and GSK461364 were combined with ionizing radiation." | 1.48 | PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs. ( Brassesco, MS; Pezuk, JA; Roberto, GM; Salomão, KB; Scrideli, CA; Tone, LG, 2018) |
| "We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1((F/F));Trp53((F/F)) mouse model of de novo mammary tumour formation." | 1.42 | Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase. ( Buijs, JT; Cheung, H; Cohen, R; Corver, WE; Guise, TA; Jonkers, J; Kruithof-de Julio, M; Matula, KM; Mohammad, KS; Snoeks, TJ; van der Mark, MH; van der Pluijm, G, 2015) |
| "Estrogen receptor (ER) α-positive breast cancers initially respond to antiestrogens but eventually become estrogen independent and recur." | 1.42 | Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. ( Abramson, V; Allen, EV; Arteaga, CL; Bafna, S; Balko, JM; Bhola, NE; Dugger, TC; Estrada, MV; Giltnane, JM; Jansen, VM; Mayer, I; Meszoely, I; Sanders, M; Ye, F, 2015) |
| "Tamoxifen resistance is a multifaceted phenomenon, characterized by the constitutive activation of multiple signaling cascades that provide an additional survival advantage to cells." | 1.42 | BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells. ( Bharti, R; Mandal, M; Parida, S; Prashanth Kumar, BN; Rajput, S, 2015) |
| " Most importantly, the administration of BI-2536, in combination with doxorubicin + cyclophosphamide chemotherapy, led to a faster complete response compared with the chemotherapy treatment alone and prevented relapse, which is the major risk associated with TNBC." | 1.39 | Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. ( Barillot, E; Cruzalegui, F; De Koning, L; Decaudin, D; Depil, S; Dubois, T; Dumont, A; Gentien, D; Gravier, E; Lang, G; Maire, V; Marangoni, E; Marty-Prouvost, B; Némati, F; Pierré, A; Richardson, M; Rigaill, G; Roman-Roman, S; Tesson, B; Tucker, GC; Vincent-Salomon, A, 2013) |
| "PLK1 was universally expressed in breast cancer cell lines, representing all of the breast cancer subtypes, and was positively correlated to CD44." | 1.38 | Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. ( Dunn, SE; Fotovati, A; Hu, K; Law, JH, 2012) |
| "DC-TA-46 was found to inhibit growth of B16 melanoma and MCF-7 mammary carcinoma cells dose dependently (B16: IC50 = 1." | 1.29 | 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. ( Drees, M; Eisenbrand, G; Zimmermann, R, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Rasmussen, L | 2 |
| Foulks, Z | 2 |
| Burton, C | 4 |
| Shi, H | 4 |
| Wu, J | 1 |
| Li, Y | 1 |
| Zhou, X | 1 |
| Liu, J | 1 |
| Gao, N | 1 |
| Yang, R | 1 |
| Wang, Q | 1 |
| Ji, J | 1 |
| Ma, L | 1 |
| He, Q | 1 |
| Montaudon, E | 1 |
| Nikitorowicz-Buniak, J | 1 |
| Sourd, L | 1 |
| Morisset, L | 1 |
| El Botty, R | 1 |
| Huguet, L | 1 |
| Dahmani, A | 1 |
| Painsec, P | 1 |
| Nemati, F | 2 |
| Vacher, S | 1 |
| Chemlali, W | 1 |
| Masliah-Planchon, J | 1 |
| Château-Joubert, S | 1 |
| Rega, C | 1 |
| Leal, MF | 1 |
| Simigdala, N | 1 |
| Pancholi, S | 1 |
| Ribas, R | 1 |
| Nicolas, A | 1 |
| Meseure, D | 1 |
| Vincent-Salomon, A | 2 |
| Reyes, C | 1 |
| Rapinat, A | 1 |
| Gentien, D | 2 |
| Larcher, T | 1 |
| Bohec, M | 1 |
| Baulande, S | 1 |
| Bernard, V | 1 |
| Decaudin, D | 2 |
| Coussy, F | 1 |
| Le Romancer, M | 1 |
| Dutertre, G | 1 |
| Tariq, Z | 1 |
| Cottu, P | 1 |
| Driouch, K | 1 |
| Bièche, I | 1 |
| Martin, LA | 1 |
| Marangoni, E | 2 |
| Saatci, Ö | 1 |
| Borgoni, S | 1 |
| Akbulut, Ö | 1 |
| Durmuş, S | 1 |
| Raza, U | 1 |
| Eyüpoğlu, E | 1 |
| Alkan, C | 1 |
| Akyol, A | 1 |
| Kütük, Ö | 1 |
| Wiemann, S | 1 |
| Şahin, Ö | 1 |
| Jeong, SB | 1 |
| Im, JH | 1 |
| Yoon, JH | 1 |
| Bui, QT | 1 |
| Lim, SC | 1 |
| Song, JM | 1 |
| Shim, Y | 1 |
| Yun, J | 1 |
| Hong, J | 1 |
| Kang, KW | 1 |
| Brassesco, MS | 1 |
| Pezuk, JA | 1 |
| Salomão, KB | 1 |
| Roberto, GM | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Wierer, M | 1 |
| Verde, G | 1 |
| Pisano, P | 1 |
| Molina, H | 1 |
| Font-Mateu, J | 1 |
| Di Croce, L | 1 |
| Beato, M | 1 |
| Stone, A | 1 |
| Cowley, MJ | 1 |
| Valdes-Mora, F | 1 |
| McCloy, RA | 1 |
| Sergio, CM | 1 |
| Gallego-Ortega, D | 1 |
| Caldon, CE | 1 |
| Ormandy, CJ | 1 |
| Biankin, AV | 1 |
| Gee, JM | 1 |
| Nicholson, RI | 1 |
| Print, CG | 2 |
| Clark, SJ | 1 |
| Musgrove, EA | 1 |
| Ma, Y | 2 |
| Buijs, JT | 1 |
| Matula, KM | 1 |
| Cheung, H | 1 |
| Kruithof-de Julio, M | 1 |
| van der Mark, MH | 1 |
| Snoeks, TJ | 1 |
| Cohen, R | 1 |
| Corver, WE | 1 |
| Mohammad, KS | 1 |
| Jonkers, J | 1 |
| Guise, TA | 1 |
| van der Pluijm, G | 1 |
| Bhola, NE | 1 |
| Jansen, VM | 1 |
| Bafna, S | 1 |
| Giltnane, JM | 1 |
| Balko, JM | 1 |
| Estrada, MV | 1 |
| Meszoely, I | 1 |
| Mayer, I | 1 |
| Abramson, V | 1 |
| Ye, F | 1 |
| Sanders, M | 1 |
| Dugger, TC | 1 |
| Allen, EV | 1 |
| Arteaga, CL | 1 |
| Prashanth Kumar, BN | 1 |
| Rajput, S | 1 |
| Bharti, R | 1 |
| Parida, S | 1 |
| Mandal, M | 1 |
| Song, C | 1 |
| Bae, Y | 1 |
| Jun, J | 1 |
| Lee, H | 1 |
| Kim, ND | 1 |
| Lee, KB | 1 |
| Hur, W | 1 |
| Park, JY | 1 |
| Sim, T | 1 |
| Schöffski, P | 1 |
| Blay, JY | 1 |
| De Greve, J | 1 |
| Brain, E | 1 |
| Machiels, JP | 1 |
| Soria, JC | 1 |
| Sleijfer, S | 1 |
| Wolter, P | 1 |
| Ray-Coquard, I | 1 |
| Fontaine, C | 1 |
| Munzert, G | 1 |
| Fritsch, H | 1 |
| Hanft, G | 1 |
| Aerts, C | 1 |
| Rapion, J | 1 |
| Allgeier, A | 1 |
| Bogaerts, J | 1 |
| Lacombe, D | 1 |
| Astanehe, A | 1 |
| Finkbeiner, MR | 1 |
| Krzywinski, M | 1 |
| Fotovati, A | 3 |
| Dhillon, J | 1 |
| Berquin, IM | 1 |
| Mills, GB | 1 |
| Marra, MA | 1 |
| Dunn, SE | 3 |
| Hu, K | 2 |
| Law, JH | 1 |
| Stratford, AL | 1 |
| Reipas, K | 1 |
| Brough, R | 1 |
| Frankum, J | 1 |
| Takhar, M | 1 |
| Watson, P | 1 |
| Ashworth, A | 1 |
| Lord, CJ | 1 |
| Lasham, A | 1 |
| Maire, V | 1 |
| Richardson, M | 1 |
| Tesson, B | 1 |
| Rigaill, G | 1 |
| Gravier, E | 1 |
| Marty-Prouvost, B | 1 |
| De Koning, L | 1 |
| Lang, G | 1 |
| Dumont, A | 1 |
| Barillot, E | 1 |
| Roman-Roman, S | 1 |
| Pierré, A | 1 |
| Cruzalegui, F | 1 |
| Depil, S | 1 |
| Tucker, GC | 1 |
| Dubois, T | 1 |
| Dhondt, JL | 1 |
| Bellhasene, Z | 1 |
| Largilliere, C | 1 |
| Bonneterre, J | 1 |
| Farriaux, JP | 1 |
| Drees, M | 1 |
| Zimmermann, R | 1 |
| Eisenbrand, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149] | Phase 2 | 76 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pteridines and Breast Cancer
| Article | Year |
|---|---|
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo | 2010 |
21 other studies available for pteridines and Breast Cancer
| Article | Year |
|---|---|
Establishing pteridine metabolism in a progressive isogenic breast cancer cell model.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Humans; Metabolomics; Pteridines | 2021 |
Establishing pteridine metabolism in a progressive isogenic breast cancer cell model - part II.
Topics: Biopterins; Breast Neoplasms; Female; Humans; Metabolomics; Pteridines; Pterins | 2022 |
Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Artemisinins; Breast Neoplasms; Carcinogenesis; Cell Lin | 2020 |
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D1; DNA Copy Number Variati | 2020 |
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; bcl-X Protein; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle | 2018 |
Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle | 2018 |
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Cycle Proteins; Cell Line, | 2018 |
PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Topics: Benzamides; Breast Neoplasms; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Chromati | 2013 |
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Topics: Antimitotic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis | 2013 |
Simultaneous detection of six urinary pteridines and creatinine by high-performance liquid chromatography-tandem mass spectrometry for clinical breast cancer detection.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Chromatography, High Pressure L | 2013 |
Normalization of urinary pteridines by urine specific gravity for early cancer detection.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Diagnosis, Differential; Early | 2014 |
Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.
Topics: Animals; Apoptosis; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Cdh1 Proteins; Cell Line, | 2015 |
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Breast Neoplasms; Cell Cycle | 2015 |
BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cellu | 2015 |
Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion.
Topics: Adenosine Triphosphate; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cycli | 2017 |
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Base Sequence; Breast Neoplasms | 2012 |
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2012 |
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Topics: Animals; Apoptosis; Benzopyrans; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Female; Flow | 2012 |
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Cell | 2013 |
[Normal and pathologic metabolism of pteridines in man].
Topics: Adolescent; Adult; Breast Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Infant, Newbor | 1982 |
3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Anion Exchange Resins; Antineoplastic Agents; B | 1993 |